Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?

Linezolid (LNZ), a group 5 antituberculous drug (unclear efficacy), was used in the starter regimens of 23 adults with multidrug-resistant tuberculosis. The LNZ-containing regimens were effective in achieving culture conversions and relapse-free outcomes. The most frequent LNZ-related side effect wa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open forum infectious diseases Jg. 2; H. 4; S. ofv175
Hauptverfasser: Grard, Soazic, Catho, Gaud, Valour, Florent, Bouaziz, Anissa, Perpoint, Thomas, Braun, Evelyne, Biron, François, Miailhes, Patrick, Ferry, Tristan, Chidiac, Christian, Souquet, Pierre-Jean, Couraud, Sébastien, Lina, Gérard, Goutelle, Sylvain, Veziris, Nicolas, Dumitrescu, Oana, Ader, Florence
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Oxford University Press 01.12.2015
Schlagworte:
Bacteriology
Brief Reports
Immunology
Life Sciences
Microbiology and Parasitology
Virology
neuropathy
ethionamide
linezolid
multidrug-resistant tuberculosis
ISSN:2328-8957, 2328-8957
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Linezolid (LNZ), a group 5 antituberculous drug (unclear efficacy), was used in the starter regimens of 23 adults with multidrug-resistant tuberculosis. The LNZ-containing regimens were effective in achieving culture conversions and relapse-free outcomes. The most frequent LNZ-related side effect was neuropathy. We propose that LNZ should be reclassified among bactericidal second-line drugs.
Bibliographie:SourceType-Scholarly Journals-1
content type line 14
ObjectType-Report-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
PMCID: PMC4690547
O. D. and F. A. contributed equally to this work.
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofv175